Abstract: Objective To perform a systematic review on the predictive value of serum HBsAg levels in patients with HBeAg positive chronic hepatitis B（CHB） treated with nucleos（t）ide analogues（NAs）. Methods A systematic search was performed on clinical trials regarding quantitative detection of serum HBsAg before and after antiviral treatment with NAs in patients with HBeAg positive CHB in PubMed,EMBASE and Cochrane Central Register between January 1,2006 and August 1,2016. Data was extracted by two reviewers independently. Statistical analysis was performed by using RevMan 5.2. HBsAg response was defined as serum HBsAg levels declined more than 1 lg IU/mL from baseline levels within 1 year after treatment with NAs. The other observation indexes were baseline HBsAg levels,HBeAg seroconversion and HBsAg loss. Results 10 eligible studies（467 patients in total） were enrolled in this Meta-analysis. The rate of HBeAg seroconversion in patients with HBsAg response was 64.3%,significantly higher than 19.8% in patients without HBsAg response（P<0.0001）;the rate of HBsAg loss in patients with HBsAg response was 30.5%,also significantly higher than 0.4% in patients without HBsAg response（P<0.05）;the baseline HBsAg levels were not shown different between patients with,（3.4±0.6 lg IU/mL） and paitents without HBeAg seroconversion（3.7±0.4 lg IU/mL,P﹥0.05）. Conclusions During the treatment with NAs,a rapid decline of serum HBsAg levels might predict serological response in HBeAg positive CHB patients.

Key words: Hepatitis B, Nucleos（t）ide analogs, HBsAg, HBeAg seroconversion, Meta-analysis